Palakkad, India

Reena Vijayaraghavan

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Biocon Limited. Active years: 2015.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Reena Vijayaraghavan: Innovator in Oligomer Synthesis

Introduction

Reena Vijayaraghavan is a notable inventor based in Palakkad, India. She has made significant contributions to the field of chemistry, particularly in the synthesis of oligomeric compounds. Her innovative approach has led to advancements that improve the efficiency and effectiveness of synthesizing these compounds.

Latest Patents

Reena holds a patent for a method of synthesizing a substantially monodispersed mixture of oligomers. This invention focuses on methods for synthesizing oligomer compounds that include polyethylene glycol moieties. The techniques she developed utilize milder and more efficacious reaction conditions compared to conventional methods, showcasing her commitment to enhancing chemical synthesis processes.

Career Highlights

Reena Vijayaraghavan is associated with Biocon Limited, a leading biopharmaceutical company. Her work at Biocon has allowed her to apply her innovative ideas in a practical setting, contributing to the company's mission of improving healthcare through biotechnology.

Collaborations

Reena has collaborated with esteemed colleagues such as Chandrashekar Aswathanarayanappa and Srinivas Pullela Venkata. These collaborations have fostered a productive environment for research and development, furthering the impact of her work in the field.

Conclusion

Reena Vijayaraghavan is a pioneering inventor whose work in oligomer synthesis has the potential to revolutionize the field of chemistry. Her innovative methods and dedication to improving synthesis processes highlight her significant contributions to science and technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…